These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 24788435)

  • 1. Fatty acid amide hydrolase (FAAH) inhibitors exert pharmacological effects, but lack antinociceptive efficacy in rats with neuropathic spinal cord injury pain.
    Hama AT; Germano P; Varghese MS; Cravatt BF; Milne GT; Pearson JP; Sagen J
    PLoS One; 2014; 9(5):e96396. PubMed ID: 24788435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment.
    Guindon J; Lai Y; Takacs SM; Bradshaw HB; Hohmann AG
    Pharmacol Res; 2013 Jan; 67(1):94-109. PubMed ID: 23127915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of effect of chronic pre-treatment with the FAAH inhibitor URB597 on inflammatory pain behaviour: evidence for plastic changes in the endocannabinoid system.
    Okine BN; Norris LM; Woodhams S; Burston J; Patel A; Alexander SP; Barrett DA; Kendall DA; Bennett AJ; Chapman V
    Br J Pharmacol; 2012 Oct; 167(3):627-40. PubMed ID: 22595021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Fatty Acid Amide Hydrolase Improves Depressive-Like Behaviors Independent of Its Peripheral Antinociceptive Effects in a Rat Model of Neuropathic Pain.
    Jiang HX; Ke BW; Liu J; Ma G; Hai KR; Gong DY; Yang Z; Zhou C
    Anesth Analg; 2019 Aug; 129(2):587-597. PubMed ID: 29863609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical and biological properties of 4-(3-phenyl-[1,2,4] thiadiazol-5-yl)-piperazine-1-carboxylic acid phenylamide, a mechanism-based inhibitor of fatty acid amide hydrolase.
    Karbarz MJ; Luo L; Chang L; Tham CS; Palmer JA; Wilson SJ; Wennerholm ML; Brown SM; Scott BP; Apodaca RL; Keith JM; Wu J; Breitenbucher JG; Chaplan SR; Webb M
    Anesth Analg; 2009 Jan; 108(1):316-29. PubMed ID: 19095868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Full inhibition of spinal FAAH leads to TRPV1-mediated analgesic effects in neuropathic rats and possible lipoxygenase-mediated remodeling of anandamide metabolism.
    Starowicz K; Makuch W; Korostynski M; Malek N; Slezak M; Zychowska M; Petrosino S; De Petrocellis L; Cristino L; Przewlocka B; Di Marzo V
    PLoS One; 2013; 8(4):e60040. PubMed ID: 23573230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice.
    Booker L; Kinsey SG; Abdullah RA; Blankman JL; Long JZ; Ezzili C; Boger DL; Cravatt BF; Lichtman AH
    Br J Pharmacol; 2012 Apr; 165(8):2485-96. PubMed ID: 21506952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition.
    Scherma M; Medalie J; Fratta W; Vadivel SK; Makriyannis A; Piomelli D; Mikics E; Haller J; Yasar S; Tanda G; Goldberg SR
    Neuropharmacology; 2008 Jan; 54(1):129-40. PubMed ID: 17904589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the fatty acid amide hydrolase inhibitor URB597 on pain-stimulated and pain-depressed behavior in rats.
    Kwilasz AJ; Abdullah RA; Poklis JL; Lichtman AH; Negus SS
    Behav Pharmacol; 2014 Apr; 25(2):119-29. PubMed ID: 24583930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of spinal and supraspinal cannabinoid-1 receptors leads to antinociception in a rat model of neuropathic spinal cord injury pain.
    Hama A; Sagen J
    Brain Res; 2011 Sep; 1412():44-54. PubMed ID: 21813113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms.
    Chang L; Luo L; Palmer JA; Sutton S; Wilson SJ; Barbier AJ; Breitenbucher JG; Chaplan SR; Webb M
    Br J Pharmacol; 2006 May; 148(1):102-13. PubMed ID: 16501580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The novel reversible fatty acid amide hydrolase inhibitor ST4070 increases endocannabinoid brain levels and counteracts neuropathic pain in different animal models.
    Caprioli A; Coccurello R; Rapino C; Di Serio S; Di Tommaso M; Vertechy M; Vacca V; Battista N; Pavone F; Maccarrone M; Borsini F
    J Pharmacol Exp Ther; 2012 Jul; 342(1):188-95. PubMed ID: 22514334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ASP8477, a fatty acid amide hydrolase inhibitor, exerts analgesic effects in rat models of neuropathic and dysfunctional pain.
    Kiso T; Watabiki T; Sekizawa T
    Eur J Pharmacol; 2020 Aug; 881():173194. PubMed ID: 32445705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain.
    Kinsey SG; Long JZ; O'Neal ST; Abdullah RA; Poklis JL; Boger DL; Cravatt BF; Lichtman AH
    J Pharmacol Exp Ther; 2009 Sep; 330(3):902-10. PubMed ID: 19502530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attenuation of persistent pain-related behavior by fatty acid amide hydrolase (FAAH) inhibitors in a rat model of HIV sensory neuropathy.
    Nasirinezhad F; Jergova S; Pearson JP; Sagen J
    Neuropharmacology; 2015 Aug; 95():100-9. PubMed ID: 25486617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The multiplicity of spinal AA-5-HT anti-nociceptive action in a rat model of neuropathic pain.
    Malek N; Kostrzewa M; Makuch W; Pajak A; Kucharczyk M; Piscitelli F; Przewlocka B; Di Marzo V; Starowicz K
    Pharmacol Res; 2016 Sep; 111():251-263. PubMed ID: 27326920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain permeant and impermeant inhibitors of fatty-acid amide hydrolase suppress the development and maintenance of paclitaxel-induced neuropathic pain without producing tolerance or physical dependence in vivo and synergize with paclitaxel to reduce tumor cell line viability in vitro.
    Slivicki RA; Xu Z; Mali SS; Hohmann AG
    Pharmacol Res; 2019 Apr; 142():267-282. PubMed ID: 30739035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice.
    Russo R; Loverme J; La Rana G; Compton TR; Parrott J; Duranti A; Tontini A; Mor M; Tarzia G; Calignano A; Piomelli D
    J Pharmacol Exp Ther; 2007 Jul; 322(1):236-42. PubMed ID: 17412883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cannabinoid subtype-2 receptors modulate the antihyperalgesic effect of WIN 55,212-2 in rats with neuropathic spinal cord injury pain.
    Ahmed MM; Rajpal S; Sweeney C; Gerovac TA; Allcock B; McChesney S; Patel AU; Tilghman JI; Miranpuri GS; Resnick DK
    Spine J; 2010 Dec; 10(12):1049-54. PubMed ID: 20920894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain.
    Jhaveri MD; Richardson D; Kendall DA; Barrett DA; Chapman V
    J Neurosci; 2006 Dec; 26(51):13318-27. PubMed ID: 17182782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.